IL308603A - Uses of antibodies against ICOS - Google Patents

Uses of antibodies against ICOS

Info

Publication number
IL308603A
IL308603A IL308603A IL30860323A IL308603A IL 308603 A IL308603 A IL 308603A IL 308603 A IL308603 A IL 308603A IL 30860323 A IL30860323 A IL 30860323A IL 308603 A IL308603 A IL 308603A
Authority
IL
Israel
Prior art keywords
icos antibodies
icos
antibodies
Prior art date
Application number
IL308603A
Other languages
English (en)
Hebrew (he)
Original Assignee
Kymab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kymab Ltd filed Critical Kymab Ltd
Priority claimed from PCT/EP2022/063450 external-priority patent/WO2022243378A1/en
Publication of IL308603A publication Critical patent/IL308603A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL308603A 2021-05-18 2022-05-18 Uses of antibodies against ICOS IL308603A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163190016P 2021-05-18 2021-05-18
PCT/EP2022/063450 WO2022243378A1 (en) 2021-05-18 2022-05-18 Uses of anti-icos antibodies

Publications (1)

Publication Number Publication Date
IL308603A true IL308603A (en) 2024-01-01

Family

ID=89324631

Family Applications (1)

Application Number Title Priority Date Filing Date
IL308603A IL308603A (en) 2021-05-18 2022-05-18 Uses of antibodies against ICOS

Country Status (6)

Country Link
EP (1) EP4340943A1 (enExample)
JP (1) JP2024518843A (enExample)
KR (1) KR20240007760A (enExample)
CN (1) CN117460529A (enExample)
AU (1) AU2022276349A1 (enExample)
IL (1) IL308603A (enExample)

Also Published As

Publication number Publication date
EP4340943A1 (en) 2024-03-27
KR20240007760A (ko) 2024-01-16
AU2022276349A1 (en) 2024-01-04
JP2024518843A (ja) 2024-05-07
CN117460529A (zh) 2024-01-26

Similar Documents

Publication Publication Date Title
GB201721338D0 (en) Anti-icos Antibodies
IL308741A (en) Anti-SIRP-alpha antibodies
IL307832A (en) Engineering of antigen-binding proteins
HUE069018T2 (hu) Anti-CCR8 antitestek
GB202105110D0 (en) Anti-CD73 antibodies
IL289842A (en) Human anti-liv1 antibodies for cancer therapy
EP4377358A4 (en) NEW ANTI-SIRPA ANTIBODIES
GB202103774D0 (en) Detectiion of Ransomware
GB202111905D0 (en) Antibodies
IL309664A (en) Administration of anti-HPA-1A antibodies
GB202014851D0 (en) SARS-COV-2 antibodies
ZA202209699B (en) Novel antibodies
IL300142A (en) Anti-IL13Ralpha2 antibodies
IL276937A (en) Using an antibody against P-selectin
EP4114547A4 (en) METHOD FOR PRODUCING HYPERSIALYLATED IMMUNOGLOBULIN
IL308603A (en) Uses of antibodies against ICOS
HK40107656A (en) Uses of anti-icos antibodies
IL284086A (en) Controlled Fucosylation of Antibodies
IL308100A (en) Antibodies
GB202001447D0 (en) Antibodies
EP3607970A4 (en) LYOPHILIZED PREPARATION OF A MONOCLONAL INFLIXIMAB ANTIBODY
HK40066304A (en) Anti-icos antibodies for the treatment of cancer
GB202108596D0 (en) Methods of selectively reducing antibodies
HK40087076A (en) Methods of making hyper-sialylated immunoglobulin
HK40131449A (en) Methods of making antibodies